Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONNECT
- Sponsors Biogen
- 24 Sep 2019 This trial was completed in Denmark, according to European Clinical Trials Database.
- 11 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated